Sponsors (2)
The bill expands and standardizes access to genomic cancer testing and boosts clinician training—likely improving diagnoses and personalized care—but raises federal/state costs, administrative burdens, and risks of overuse, denials, and uneven access.
Medicare, Medicaid, and CHIP beneficiaries (including low-income adults and children) will gain guaranteed coverage for genomic cancer diagnostic tests—Medicare beneficiaries also face no Part B deductible for covered tests—and Medicaid benchmark requirements will standardize access across states.
Physicians, genetic counselors, and other healthcare workers will receive expanded genomic-testing training and public awareness will increase, improving diagnosis, earlier detection of actionable mutations, and more personalized cancer care.
Laboratories and providers will have more predictable reimbursement rules (payment formulas and assignment rules), reducing billing uncertainty and helping lab and provider financial planning.
Taxpayers and federal/state programs (Medicare, Medicaid, CHIP) will face higher spending to cover advanced genomic tests and related training programs, increasing budgetary pressure and potential trade-offs for other services.
States will incur administrative, budgetary, and possibly legislative burdens to implement mandatory Medicaid coverage and benchmark-equivalent plan changes effective 2027.
Expanded coverage may incentivize increased utilization of genomic tests, driving higher overall healthcare spending and raising the risk of unnecessary or low-value testing.
Based on analysis of 3 sections of legislative text.
Requires Medicare, Medicaid, and CHIP to cover defined cancer diagnostic and genomic tests, sets Medicare payment rules and timelines, and creates an HHS genomic testing education program.
Introduced February 26, 2025 by Roger F. Wicker · Last progress February 26, 2025
Requires Medicare, Medicaid, and CHIP to cover specified cancer diagnostic and genomic laboratory tests (including sequencing and interpretation) and sets timing and payment rules for Medicare and effective dates for Medicaid and CHIP. Directs HHS, with the National Human Genome Research Institute, to run an education and awareness program for clinicians and the public about genomic testing and to encourage inclusion of molecular diagnostics training in medical education and continuing education. Coverage changes take effect on different schedules: Medicare coverage becomes available six months after enactment, CHIP coverage begins January 1, 2025, and the Medicaid changes become effective for items and services furnished on or after January 1, 2027 (with a state legislative transition rule).